Inclusion Criteria:

- Histologically or cytologically confirmed advanced malignant solid tumor that is
refractory to, intolerant of, or for which no standard of therapy is available

- Measurable or evaluable disease

- ECOG Performance Status of ≤2

- No known active central nervous system (CNS) tumors or CNS metastases

- Adequate organ function

Exclusion Criteria:

- Myocardial infarction within the last 6 months of study Day 1, symptomatic congestive
heart failure (New York Heart Association Classification > Class II), unstable
angina, or unstable cardiac arrhythmia requiring medication

- History of surgery within 28 days prior to enrollment or anticipated surgery during
the study period

- Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy,
retinoid therapy, hormonal therapy) within 28 days of study Day 1 (six weeks for
nitrosoureas, mitomycin C, antibodies, or molecular agents with t½ >10 days);
(concurrent use of hormone therapy for breast or prostate cancer is permitted)

- Treatment with immune modulators including, but not limited to, cyclosporine and
tacrolimus within two weeks prior to enrollment

- Concurrent or prior (within 30 days of study Day 1) anticoagulation therapy;
(low-dose warfarin [<2 mg/day] for prophylaxis against central venous catheter
thrombosis is allowed)

- Patient with tumor that is infiltrating or invading a major blood vessel